Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combidex Broad Indication Appropriateness To Be Topic For Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA questions whether Combidex can be used to detect metastatic lymph nodes in a broad range of cancer types. The agency will also ask the committee to discuss the product’s risk of anaphylactic/anaphylactoid reactions and recommend strategies to mitigate the risk.

You may also be interested in...



Advanced Magnetics Combidex “Complete Response”

Advanced Magnetics' Combidex NDA has a user fee goal date of March 30, 2005

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

Sepracor Lunesta Ads Are Top At Brand Recognition, IAG Research Finds

Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel